https://www.pharmanow.live/latest-news/biological-e-appoints-v-krishnakumar-ceo-biopharma-cdmo 2026-10-03T13:43:23+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 Biological E Appoints V Krishnakumar CEO Of Global Biopharma CDMO Biological E https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/6ac409e4-9c3f-43f0-8630-9d4a57ff0cdb/768e568c-f325-4ab4-83c1-4016f8df73cc.png https://www.pharmanow.live/latest-news/zydus-lifesciences-extends-sunshine-healthcare-lanka-jv-deadline-december-2026 2026-10-03T13:44:22+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 Zydus Extends Sunshine Healthcare JV Timeline To December 2026 Zydus https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/6ac409e4-9c3f-43f0-8630-9d4a57ff0cdb/9fa0e768-4ca7-4c8d-a69d-599c169c0178.png https://www.pharmanow.live/latest-news/godavari-biorefineries-secures-mexican-patent-antiviral-compounds 2026-10-03T13:46:49+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 Godavari Biorefineries Secures Mexican Antiviral Patent Godavari https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/6ac409e4-9c3f-43f0-8630-9d4a57ff0cdb/538cf8f1-9dac-4602-899d-33deee0307d0.png https://www.pharmanow.live/latest-news/bayer-2-2-billion-us-manufacturing-site-reshoring 2026-10-03T14:20:33+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 Bayer Commits $2.2 Billion To New U.S. Sites Amid Reshoring Drive Bayer https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bayer-2-2-billion-us-manufacturing-site-reshoring-202620261003142026.webp https://www.pharmanow.live/latest-news/novo-nordisk-denecimig-bla-review-extended-fda-facility-remediation 2026-10-03T14:12:22+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Plant Inspection Delays Novo Nordisk Denecimig BLA Review Now FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/novo-nordisk-denecimig-bla-review-extended-fda-facility-remediation-202620261003141211.webp https://www.pharmanow.live/latest-news/eli-lilly-fda-approval-pirtobrutinib-first-line-cll-sll 2026-10-03T13:13:19+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Approves Lilly Pirtobrutinib For First Line CLL SLL Patients FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/eli-lilly-fda-approval-pirtobrutinib-first-line-cll-sll-202620261003131309.webp https://www.pharmanow.live/latest-news/fda-updates-hctp-non-blood-biologics-deviation-reporting-codes-october-2026 2026-10-03T13:09:39+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Updates Deviation Codes For Biologics Effective October 2026 FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-hctp-non-blood-biologics-deviation-reporting-codes-october-202620261003130936.webp https://www.pharmanow.live/latest-news/fda-updates-biological-product-deviation-reporting-blood-product-codes-october-2026 2026-10-03T13:04:58+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Updates Blood Product Deviation Codes Effective October 2026 FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-biological-product-deviation-reporting-blood-product-codes-october-202620261003130446.webp https://www.pharmanow.live/latest-news/abbvie-hrsa-340b-rebate-model-pilot-imbruvica-linzess-vraylar-2027 2026-10-03T12:59:38+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 AbbVie Joins HRSA 340B Rebate Pilot For Three Drugs January 2027 AbbVie https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-hrsa-340b-rebate-model-pilot-imbruvica-linzess-vraylar-202720261003125925.webp https://www.pharmanow.live/latest-news/fda-transparency-roadmap-complete-response-letters-fy27-priorities 2026-10-03T12:52:37+05:30 Pharma Now en 2026-10-03T00:00:00+05:30 FDA Releases Transparency Roadmap With Complete Response Letters Now FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-transparency-roadmap-complete-response-letters-fy27-priorities-202620261003125137.webp https://www.pharmanow.live/latest-news/lilly-oral-glp1-diabetes-heart-disease-risk-reduction-solid-dosage-scale-up 2026-10-03T11:49:44+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Lilly Achieves Oral GLP-1 Risk Reduction Data Signaling Solid Dosage Scale-Up Demand Lilly https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lilly-oral-glp1-diabetes-heart-disease-risk-reduction-solid-dosage-scale-up-202620261003114925.webp https://www.pharmanow.live/latest-news/tapi-appoints-serge-rogasik-ceo-global-api-cdmo-expansion 2026-10-03T11:45:54+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 TAPI Appoints Serge Rogasik as CEO to Drive Global API and CDMO Expansion TAPI Appoints Serge Rogasik https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/tapi-serge-rogasik-ceo-global-api-cdmo-expansion-202620261003114548.webp https://www.pharmanow.live/latest-news/roche-faricimab-vabysmo-real-world-durability-retinal-disease-data 2026-10-03T11:43:15+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Roche Real-World Data Confirm Faricimab Durability Across Multiple Retinal Disease Indications Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-faricimab-vabysmo-real-world-durability-retinal-disease-data-202620261003114149.webp https://www.pharmanow.live/latest-news/roche-giredestrant-phase3-pfs-benefit-er-positive-breast-cancer 2026-10-03T11:37:02+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Roche Achieves Significant PFS Benefit with Giredestrant in Phase 3 ER+/HER2- Breast Cancer Trial Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-giredestrant-phase-3-pfs-benefit-er-positive-breast-cancer-202620261003113700.webp https://www.pharmanow.live/latest-news/teva-ecopipam-phase3-ole-data-fda-priority-review-pediatric-tourette-syndrome 2026-10-03T11:33:42+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Teva Presents Ecopipam Phase 3 and OLE Data Supporting FDA Priority Review for Pediatric Tourette Syndrome Teva https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/teva-ecopipam-phase-3-ole-data-fda-priority-review-pediatric-tourette-syndrome-202620261003113250.webp https://www.pharmanow.live/latest-news/teva-ecopipam-d1-receptor-tourette-syndrome-pediatric-journal-child-neurology 2026-10-03T11:15:51+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Teva Gains Journal Validation for Ecopipam's First-in-Class D1 Mechanism in Pediatric Tourette Syndrome Teva https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/teva-ecopipam-d1-receptor-tourette-syndrome-pediatric-neurology-202620261003111538.webp https://www.pharmanow.live/latest-news/fda-ich-m15-webinar-model-informed-drug-development-october-2026 2026-10-03T12:43:42+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 FDA Hosts ICH M15 Webinar to Clarify Model-Informed Drug Development Submission Standards on October 29 ICH M15 https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-ich-m15-webinar-model-informed-drug-development-october-202620261003111234.webp https://www.pharmanow.live/latest-news/bristol-myers-squibb-fda-pediatric-approval-camzyos-obstructive-hypertrophic-cardiomyopathy 2026-10-03T10:59:40+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Bristol Myers Squibb Gains FDA Pediatric Approval for Camzyos in Obstructive Hypertrophic Cardiomyopathy FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bristol-myers-squibb-fda-pediatric-approval-camzyos-obstructive-hypertrophic-cardiomyopathy-202620261003105926.webp https://www.pharmanow.live/latest-news/bespak-nasadose-ultra-soft-spray 2026-10-02T18:08:43+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Bespak Expands Nasal Drug Delivery Portfolio with NasaDose Ultra NasaDose Ultra, Bespak, NasaDose Ultra Soft Unit Dose Spray, Resyca, Upperton, nasal drug delivery, soft mist technology, unit dose nasal spray, nose-to-brain delivery https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bespak-nasadose-ultra-soft-unit-dose20261002180347.webp https://www.pharmanow.live/latest-news/pharma-nows-inside-cdmo-behind-the-glass-goes-inside-drug-delivery-engineering-with-phillips-medisizes-justin-westendorf 2026-10-02T20:12:15+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Pharma Now's "Inside CDMO: Behind the Glass" Goes Inside Drug-Delivery Engineering with Phillips Medisize's Justin Westendorf Inside CDMO podcast, Justin Westendorf Phillips-Medisize, drug-delivery device design, Pharma Now CDMO series, CPHI Milan CDMO https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/JustinWestendorf,Director-GlobalR&DatPhillipsMedisize20261002175110.png https://www.pharmanow.live/latest-news/adarx-pharmaceuticals-closes-602m-ipo-private-placement-sirna-pipeline 2026-10-02T18:45:52+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Adarx Closes A $602.5M IPO And Private Placement For SiRNA Runway ADARx https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/adarx-pharmaceuticals-602m-ipo-private-placement-sirna-pipeline-202620261002184543.webp https://www.pharmanow.live/latest-news/greenwich-rx-recalls-compounded-glutathione-elevated-endotoxin-levels 2026-10-02T18:43:52+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 Greenwich Rx Recalls Glutathione Injections Over Endotoxin Levels Greenwich https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/greenwich-rx-compounded-glutathione-recall-elevated-endotoxin-levels-202620261002184142.webp https://www.pharmanow.live/latest-news/fda-launches-c3ti-demonstration-program-bayesian-pragmatic-trial-integration 2026-10-02T18:23:00+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 FDA Launches C3TI Program To Accelerate Pragmatic Trial Workflows FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-c3ti-demonstration-program-bayesian-pragmatic-trial-integration-202620261002182250.webp https://www.pharmanow.live/latest-news/fda-office-of-generic-drugs-leadership-divisional-structure-anda-filers 2026-10-02T10:38:37+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 OGD Publishes Full Leadership And Divisional Structures For ANDAs OGD https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/63943c32-40d2-4356-bdbe-3cffdfc97d87/502c6593-dd2d-449a-9eeb-45d000c53f66.png https://www.pharmanow.live/latest-news/fda-cder-rare-diseases-team-arc-program-orphan-drug-incentives 2026-10-02T17:57:29+05:30 Pharma Now en 2026-10-02T00:00:00+05:30 FDA Outlines ARC Commitments And Orphan Drug Incentive Framework FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-cder-rare-diseases-team-arc-program-orphan-drug-incentives-202620261002174547.webp https://www.pharmanow.live/latest-news/zealand-pharma-opens-cambridge-research-hub-biologics-hybrid-modalities 2026-10-01T22:58:16+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Zealand Pharma Opens Cambridge Hub, Expands Biologics and Hybrid Modalities Zealand Pharma https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml-eu.globenewswire.com/Resource/Download/8e29e5a2-c1b8-45ea-89df-ae72dbee1c4a https://www.pharmanow.live/latest-news/ema-advances-new-pharmaceutical-legislation-implementation-antibiotic-vouchers-regulatory-sandbox 2026-10-02T16:33:07+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 EMA Advances New Pharmaceutical Legislation Implementation, Prioritising Antibiotic Vouchers and Regulatory Sandbox EMA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ema-new-pharmaceutical-legislation-implementation-antibiotic-vouchers-regulatory-sandbox-202620261002163253.webp https://www.pharmanow.live/latest-news/ema-type-ia-variation-deadline-november-2026 2026-10-02T16:29:26+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 EMA Sets 20 November 2026 Deadline for Type IA Variations to Secure Year-End Outcomes EMA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ema-type-ia-variation-deadline-november-202620261002162918.webp https://www.pharmanow.live/latest-news/regeneron-ubamatamab-73-percent-response-rate-lgsoc-phase-1-2-trial 2026-10-02T16:20:26+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Regeneron Achieves 73% Response Rate with Ubamatamab in Phase 1/2 LGSOC Trial Regeneron https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/regeneron-ubamatamab-73-percent-response-rate-lgsoc-phase-1-2-trial-202620261002162016.webp https://www.pharmanow.live/latest-news/achieve-life-sciences-appoints-benjamin-halladay-cfo-cytisinicline 2026-10-02T16:17:36+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Achieve Life Sciences Appoints Benjamin Halladay as CFO Ahead of Cytisinicline Commercialization Achieve Life Sciences https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/achieve-life-sciences-benjamin-halladay-cfo-cytisinicline-202620261002161728.webp https://www.pharmanow.live/latest-news/spyglass-pharma-acquires-avs-iol-manufacturing-phase-3 2026-10-02T16:09:25+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 SpyGlass Pharma Acquires AVS in $13M Deal to Secure IOL Manufacturing SpyGlass https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/spyglass-pharma-avs-iol-manufacturing-phase-3-202620261002160912.webp https://www.pharmanow.live/latest-news/60-degrees-pharmaceuticals-tafenoquine-babesiosis-interim-data-october-2026 2026-10-02T16:05:15+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 60 Degrees Pharmaceuticals Releases Tafenoquine Babesiosis Interim Data 60 Degrees https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/60-degrees-pharmaceuticals-tafenoquine-babesiosis-interim-data-october-202620261002160504.webp https://www.pharmanow.live/latest-news/regeneron-trevogrumab-courage-trial-muscle-preservation-glp1 2026-10-02T16:01:43+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Regeneron Achieves Phase 2 COURAGE Trial Milestone Confirming Trevogrumab Preserves Muscle Mass During GLP-1 Weight Loss Regeneron https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/regeneron-trevogrumab-courage-trial-muscle-preservation-glp1-202620261002160128.webp https://www.pharmanow.live/latest-news/abbvie-upadacitinib-76-week-repigmentation-non-segmental-vitiligo 2026-10-02T15:44:56+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 AbbVie Achieves 76-Week Repigmentation Data for Upadacitinib in Non-Segmental Vitiligo AbbVie https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-upadacitinib-76-week-vitiligo-repigmentation-202620261002154448.webp https://www.pharmanow.live/latest-news/cardinal-health-cvs-health-distribution-agreement-extension-2032 2026-10-02T15:19:04+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Cardinal Health Signs CVS Health Distribution Extension Cardinal Health https://www.pharmanow.live/latest-news/integrated-process-solutions-for-modern-manufacturing 2026-10-01T14:48:15+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Integrated Process Solutions for Modern Manufacturing Dec Group process solutions, pharmaceutical manufacturing automation, integrated process engineering, Frederic Dietrich Dec Group, powder handling to aseptic filling https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/Image(87)20261001144236.png https://www.pharmanow.live/latest-news/lilly-retatrutide-phase-3-weight-loss-diabetes-trial 2026-10-02T15:41:06+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Lilly Retatrutide Phase 3 Trial Yields 20.8% Diabetes Weight Loss Lilly Retatrutide https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lilly-retatrutide-phase-3-weight-loss-type-2-diabetes-202620261002154054.webp https://www.pharmanow.live/latest-news/roche-fda-priority-review-fenebrutinib-multiple-sclerosis 2026-10-02T15:33:45+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Roche Fenebrutinib Gets FDA Priority Review In Two MS Indications Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-fda-priority-review-fenebrutinib-multiple-sclerosis-202620261002153339.webp https://www.pharmanow.live/latest-news/acrotech-biopharma-launches-adquey-us-dermatology-fda-approval 2026-10-02T15:29:12+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Acrotech Launches Topical PDE4 Inhibitor ADQUEY In US Via FDA Nod Acrotech https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/acrotech-biopharma-adquey-fda-approval-us-dermatology-202620261002152752.webp https://www.pharmanow.live/latest-news/shilpa-biologicals-launches-sb-himax-platform-biologics-development 2026-10-02T15:23:15+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Shilpa Biologicals Launches SB HiMax Biologics Speed Platform Shilpa Biologicals https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/shilpa-biologicals-sb-himax-biologics-development-platform-202620261002152305.webp https://www.pharmanow.live/latest-news/lilly-zepbound-superior-weight-loss-wegovy-hd-72-week-analysis 2026-10-02T15:13:02+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Lilly Zepbound Beats Wegovy HD Weight Loss In 72-Week Trial Lilly Zepbound https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lilly-zepbound-superior-weight-loss-wegovy-hd-72-week-analysis-202620261002151249.webp https://www.pharmanow.live/latest-news/sanofi-regeneron-expand-alliance-long-acting-immunology-antibodies 2026-10-02T15:01:41+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Sanofi And Regeneron Expand Immunology Alliance In $8B Grand Deal Sanofi https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/sanofi-regeneron-expand-alliance-long-acting-immunology-antibodies-202620261002150136.webp https://www.pharmanow.live/latest-news/roche-giredestrant-evera-phase-iii-pfs-dual-pdufa-2026 2026-10-02T13:19:29+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Roche Phase III PFS Gains Hits Ahead Of Dual 2026 PDUFA Deadlines Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-giredestrant-evera-phase-3-pfs-dual-pdufa-202620261002131920.webp https://www.pharmanow.live/latest-news/regeneron-sanofi-alliance-expansion-long-acting-immunology-antibodies-2026 2026-10-02T14:53:47+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Regeneron & Sanofi Sign $8B Expansion For Four Long Antibodies Regeneron https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/regeneron-sanofi-alliance-expansion-long-acting-immunology-antibodies-202620261002131146.webp https://www.pharmanow.live/latest-news/fda-domperidone-expanded-access-supply-closure-ind-importation 2026-10-02T13:04:57+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Ends Domperidone Access Supply; New IND Import Path Open FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-domperidone-expanded-access-supply-closure-ind-importation20261002130449.webp https://www.pharmanow.live/latest-news/abbvie-zumilokibart-phase-2-atopic-dermatitis 2026-10-02T13:03:38+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Abbvie Zumilokibart Meets Easi 75; Key Cmc Qa Phase Three Roadmap AbbVie https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-zumilokibart-phase-2-atopic-dermatitis-202620261002130014.webp https://www.pharmanow.live/latest-news/zealand-pharma-survodutide-phase-iii-synchronize-2-weight-loss-type-2-diabetes 2026-10-02T12:56:46+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Zealand Survodutide Gains 13.1% Weight Loss In Phase 3 Trial Zealand Survodutide https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/zealand-pharma-survodutide-phase-3-synchronize-2-weight-loss-type-2-diabetes-202620261002125637.webp https://www.pharmanow.live/latest-news/boehringer-ingelheim-survodutide-phase-iii-synchronize-2-weight-loss-results 2026-10-01T13:57:03+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Boehringer Survodutide Shows 13.1% Weight Loss In Phase III Trial Boehringer Survodutide https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml-eu.globenewswire.com/Resource/Download/d5e21fe1-beec-4d8a-8d99-4b080026b68f https://www.pharmanow.live/latest-news/fda-refreshes-drug-interaction-guidance-index-m12-october-2024-labeling 2026-10-02T12:53:06+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Refreshes M12 Drug Interaction And Oct Labeling Index FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/69cd8e88-0157-4306-b299-79603844e459.png https://www.pharmanow.live/latest-news/fda-biopharmaceutical-manufacturing-fellowship-curia-global-office-pharmaceutical-quality 2026-10-02T12:51:05+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Biotech Fellowship Places Fellows At Curia And OPQ Office FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-biopharmaceutical-manufacturing-fellowship-curia-global-office-pharmaceutical-quality20261002125055.webp https://www.pharmanow.live/latest-news/fda-cder-guidance-taxonomy-cmc-cgmp-ich-quality-categories 2026-10-01T19:04:43+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Publishes Updated CDER Guidance On CMC, CGMP, And ICH FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-cder-guidance-taxonomy-cmc-cgmp-ich-quality-categories20261001183921.webp https://www.pharmanow.live/latest-news/bristol-myers-squibb-fda-approval-camzyos-pediatric-ohcm 2026-10-02T12:34:45+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Bristol Myers Squibb Camzyos Wins Fda Approval For Pediatric Ohcm Bristol Myers https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bristol-myers-squibb-fda-approval-camzyos-pediatric-ohcm-202620261002123428.webp https://www.pharmanow.live/latest-news/fda-updates-biological-product-deviation-codes-cber-reporting 2026-10-02T12:29:54+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Updates Biological Product Deviation Codes For Cber Reporting FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-biological-product-deviation-codes-cber-reporting-202620261002122946.webp https://www.pharmanow.live/latest-news/tapi-appoints-serge-rogasik-ceo-cdmo-growth-supply-chain 2026-10-02T12:27:16+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Tapi Appoints Serge Rogasik As Ceo To Drive Cdmo Growth Expansion Tapi https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/tapi-serge-rogasik-ceo-cdmo-growth-supply-chain-202620261002122353.webp https://www.pharmanow.live/latest-news/fda-updates-biosimilars-action-plan-bsufa-iii 2026-10-02T12:12:34+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Updates Biosimilars Action Plan To Align With Bsufa Iii Goals FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-biosimilars-action-plan-bsufa-iii-202620261002121033.webp https://www.pharmanow.live/latest-news/fda-e2br3-icsr-submission-toolkit-xml-schema-aems-regional-guide 2026-10-01T18:33:13+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Consolidates E2b Icsr Submission Toolkit With Regional Guides FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-e2br3-icsr-submission-toolkit-xml-schema-aems-regional-guide20261001183306.webp https://www.pharmanow.live/latest-news/fda-aems-e2br3-e2d-r1-icsr-submission-standards-2026 2026-10-01T18:29:53+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Aems Accepts E2b(R3) Updates Aligned With Ich E2d Standards FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-aems-e2br3-e2d-r1-icsr-submission-standards-202620261001182900.webp https://www.pharmanow.live/latest-news/fda-aems-e2b-r3-icsr-mandate-october-2026 2026-10-01T18:26:02+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Mandates E2b Standard For All Icsr Submissions Via Aems Today FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-aems-e2b-r3-icsr-mandate-october-202620261001182454.webp